Taken together, these baseline characteristics show a marked trend toward less severe disease in patients in the APOLLO-B, ATTRibute-CM, and HELIOS-B studies, compared with those in the older ATTR-ACT trial (Figure 1 ).
1
—
—
Taken together, these baseline characteristics show a marked trend toward less severe disease in patients in the APOLLO-B, ATTRibute-CM, and HELIOS-B studies, compared with those in the older ATTR-ACT trial (Figure 1 ).